Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma by Dirk Schadendorf, Ralf Gutzmer, Caroline Robert, Celeste Lebbe, Gabriella Liszkay, Inge Marie Svane, Omid Hamid, Paolo Antonio Ascierto, Catriona McNeil, Claus Garbe, Michele Maio, Vanna Chiarion-Sileni, Luc Thomas, Andrzej Mackiewicz, Carmen Loquai, Ana Arance, Piotr Rutkowski, Laurent Mortier, Lars Bastholt, Brigitte Dreno, Marta Nyakas, Jean-Jacques Grob, Michael Smylie, Christoph Hoeller, Virginia Ferraresi, Florent Grange, Joanna Pikiel, Fareeda Hosein, Burcin Simsek, Michele Del Vecchio

Get full text